// App-Quantinova.ai

BSH2020‐PO‐107 : Real world, multi‐centre experience of daratumumab monotherapy and response to subsequent treatments in relapsed/refractory myeloma

Researchers

Presenter

  • J. Taube

Principal Investigators

  • M. Holt

  • J. Carmichael

  • S. Feyler

  • S. Cheesman

  • L. Lee

  • X. Papanikolaou

  • S. Mahmood

  • S. Sachchithanantham

  • J. Sive

  • C. Kyriakou

  • A. Wechalekar

  • R. Popat

  • K. Yong

  • G. Cook

  • N. Rabin

Medical Centers

  • Haematology Department, University College London Hospitals, London, UK

  • Haematology Department, St James's University Teaching Hospital

  • Leeds Institute of Medical Research, University of Leeds, Leeds

  • Haematology Department, Huddersfield Royal Infirmary, Huddersfield

  • National Amyloidosis Centre UCL and Royal Free Hospital, London, UK

  • Clinical trials research unit

  • , NIHR

  • IVD Cooperative, Leeds Cancer Centre, Leeds, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved